New hope for bile duct cancer: triple therapy shows promise after chemo fails
NCT ID NCT04834674
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This Phase 2 trial tested a combination of three treatments—local chemotherapy delivered via beads into the liver, a targeted drug called apatinib, and an immunotherapy (PD-1 antibody)—in 20 patients with advanced bile duct cancer that had worsened after standard first-line chemotherapy. The goal was to see if this approach could shrink tumors and delay progression. The study is completed, and results will show whether this combination is safe and effective enough to become a new second-line option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination of drug-eluting beads transarterial chemoembolization (DEB-TACE), apatinib, and a PD-1 antibody
What this could lead to
If successful, this combination could offer a new second-line treatment option for patients with advanced bile duct cancer who have run out of standard options.
What could go wrong
This is a small Phase 2 trial with only 20 participants, so results may not apply to everyone. The combination therapy also carries risks like liver damage, bleeding, and immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.